Ingrid Oakley-Girvan, PhD, MPH, BS

Dr. Oakley-Girvan’s key accomplishments include being the first to document a dearth of validated mobile health applications and approaches for cancer care (including symptoms) at any point in the cancer continuum, pivotal clinical trials and research work in mobile and digital technology; particularly in oncology, device utilization, and behavioral health interventions. She has documented disparities in breast and prostate cancer in addition to investigating biomarkers – both digital and lab bench based eg: genetics and proteins. A hallmark of her work is combining multi-disciplinary studies and technology with business partnerships to more rapidly advance a direct-to-patient approach for impactful work that improves delivery of care and individual and population health.

She received her Ph.D. from Stanford University School of Medicine, her M.P.H. from Tulane University School of Public Health and Tropical Medicine and her B.S. from the University of Michigan. She is currently the Director of the Data and Technology Proving Ground at the Public Health Institute and Senior Vice President of Research and Strategy at Medable Inc. She is affiliated with the Canary Center at Stanford for Cancer Early Detection and the Stanford Cancer Institute. She serves on several scientific boards, councils, and committees. These include the Cancer Patient Advocacy Alliance board and the External Advisory Board for UCSF’s Wisdom Study, the Small Business Technology Council and Economic Development Committee for the National Small Business Association, and Real World Data and Digital Biomarkers committees for the Clinical Trials Transformation Initiative. She is an active member of the American Association of Cancer Researchers, the American Public Health Association, the American Association of University Women, the American Society of Preventive Oncology, the Association for Women in Science, the Agency for Healthcare Research and Quality Patient-Centered Clinical Decision Support (CDS) Learning Network with the Patient-facing CDS Demonstration Working Group, the PROMIS Health Organization, NCI’s Research to Reality community, the MIT Technology Review Global Panel, and the Association of Clinical Research Professionals. She also served on the Stanford Clinical Trials Scientific Review Committee for 9 years and has been a reviewer for BMC Medical Genetics, American Journal of Preventive Medicine, Journal of Immigrant and Minority Health, Cancer, International Journal of Cancer, PLOS One, Cancer Causes and Control, Journal of Medical Internet Research and applications to NIH for federal funding. She has received multiple funding awards from NIH, NCI, DOD, SAMHSA, SEER, and CDC and presented at scientific and health care conferences.